Share. Connect. Create. Grow. · Socialiya
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates

CrossBridge Bio's pipeline includes a potential best-in-class TROP2-targeting TOP1i/ATRi dual-payloa...

BUSINESS NEWS April 14, 2026

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates

CrossBridge Bio's pipeline includes a potential best-in-class TROP2-targeting TOP1i/ATRi dual-payload ADC anticipated to enter the clinic in 2026.

25 views 0 likes 0 comments
Share:
CrossBridge Bio's pipeline includes a potential best-in-class TROP2-targeting TOP1i/ATRi dual-payload ADC anticipated to enter the clinic in 2026.

Author: Business Wire

Read Original Article

Related News

Latest News

Advertisement

Top Categories

Advertisement
Advertisement
Advertisement
Advertisement